# C_2014325EN.01000601.xml

| 19.9.2014 | EN | Official Journal of the European Union | C 325/6 |
| --- | --- | --- | --- |

19.9.2014

EN

Official Journal of the European Union

C 325/6

---

Prior notification of a concentration

(Case M.7339 — AbbVie/Shire)

(Text with EEA relevance)

2014/C 325/07

| 1. | On 11 September 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings AbbVie Inc. (‘AbbVie’, United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Shire Inc. (‘Shire’, Ireland) by way of purchase of shares. |
| --- | --- |

1.

On 11 September 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings AbbVie Inc. (‘AbbVie’, United States) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Shire Inc. (‘Shire’, Ireland) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   for AbbVie: a research-based biopharmaceutical company, mainly active in the discovery, development, manufacture and sale of proprietary pharmaceutical products, active globally,
  —   for Shire: a biopharmaceutical company with focus on rare diseases, neuroscience, gastrointestinal diseases and internal medicine, active globally. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for AbbVie: a research-based biopharmaceutical company, mainly active in the discovery, development, manufacture and sale of proprietary pharmaceutical products, active globally,

for AbbVie

—   for Shire: a biopharmaceutical company with focus on rare diseases, neuroscience, gastrointestinal diseases and internal medicine, active globally.

for Shire

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7339 — AbbVie/Shire, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7339 — AbbVie/Shire, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---